Quote | 23andMe Holding Co. (NASDAQ:ME)
Last: | $0.5868 |
---|---|
Change Percent: | 2.7% |
Open: | $0.581 |
Close: | $0.5868 |
High: | $0.61 |
Low: | $0.5741 |
Volume: | 2,165,031 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | 23andMe Holding Co. (NASDAQ:ME)
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRA ...
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resul...
Message Board Posts | 23andMe Holding Co. (NASDAQ:ME)
Subject | By | Source | When |
---|---|---|---|
ME 23andMe Holding Company | mick | investorshub | 04/30/2023 11:08:22 PM |
Have 12k shares here now. The data here | Afterhoursearnings3 | investorshub | 04/19/2023 5:16:04 PM |
ME 23andMe Holding Company | mick | investorshub | 04/15/2023 3:50:12 PM |
ME 23andMe Holding Company | mick | investorshub | 02/27/2023 2:23:44 AM |
ME 23andMe Holding Company | mick | investorshub | 02/21/2023 11:50:45 PM |
News, Short Squeeze, Breakout and More Instantly...
23andMe Holding Co. Company Name:
ME Stock Symbol:
NASDAQ Market:
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRA ...
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmac...
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resul...